| Schedule of net loss attributable to non-controlling interest |
|
|
BioCorRx
Pharmaceuticals,
Inc.
|
|
|
Joseph
DeSanto
MD
|
|
Net Income/(Loss) |
|
$ |
(1,917,873 |
) |
|
$ |
(13 |
) |
Average Non-controlling interest percentage of profit/losses |
|
|
24.20 |
% |
|
|
35.00 |
% |
Net Income(loss) attributable to the non-controlling interest for the three months ended September 30, 2025 |
|
$ |
(464,126 |
) |
|
$ |
(5 |
) |
|
|
BioCorRx
Pharmaceuticals,
Inc.
|
|
|
Joseph
DeSanto
MD
|
|
Net Income/(Loss) |
|
$ |
(106,233 |
) |
|
$ |
244 |
|
Average Non-controlling interest percentage of profit/losses |
|
|
24.20 |
% |
|
|
35.00 |
% |
Net loss attributable to the non-controlling interest for the three months ended September 30, 2024 |
|
$ |
(25,708 |
) |
|
$ |
85 |
|
|
|
BioCorRx
Pharmaceuticals,
Inc.
|
|
|
Joseph
DeSanto
MD
|
|
Net Income/(Loss) |
|
$ |
(3,992,701 |
) |
|
$ |
(15 |
) |
Average Non-controlling interest percentage of profit/losses |
|
|
24.20 |
% |
|
|
35.00 |
% |
Net Income(loss) attributable to the non-controlling interest for the Nine months ended September 30, 2025 |
|
$ |
(966,233 |
) |
|
$ |
(5 |
) |
|
|
BioCorRx
Pharmaceuticals,
Inc.
|
|
|
Joseph
DeSanto
MD
|
|
Net Income/(Loss) |
|
$ |
(175,033 |
) |
|
$ |
(1,720 |
) |
Average Non-controlling interest percentage of profit/losses |
|
|
24.20 |
% |
|
|
35.00 |
% |
Net loss attributable to the non-controlling interest for the Nine months ended September 30, 2024 |
|
$ |
(42,358 |
) |
|
$ |
(602 |
) |
|
| Schedule of changes in non-controlling interest |
Balance, December 31, 2024 |
|
$ |
(234,812 |
) |
Net loss attributable to the non-controlling interest |
|
|
- |
|
Balance, September 30, 2025 |
|
$ |
- |
|
Balance, December 31, 2023 |
|
$ |
(128,834 |
) |
Net loss attributable to the non-controlling interest |
|
|
(42,960 |
) |
Balance, September 30, 2024 |
|
$ |
(171,794 |
) |
|